NCT02739386View on ClinicalTrials.gov

Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases

CompletedOBSERVATIONAL
Enrollment

370

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 30, 2017

Study Completion Date

March 30, 2017

Conditions
Melanoma
Interventions
BIOLOGICAL

Ipilimumab

Intravenous monoclonal antibody injection

Trial Locations (1)

08540

Bristol-Myers Squibb, Princeton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY